Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Vaccine Passport Potential Could Boost These 7 Pharmaceutical Stocks

By Chris Lau, InvestorPlace Contributor

Nearly everyone will get the Covid-19 vaccination, suggesting strong revenue for a handful of pharmaceutical companies.

Ripple Is a Great Long-Term Buy No Matter What Happens With the SEC

By Chris Lau, InvestorPlace Contributor

The SEC’s suit against Ripple is a regulatory risk hurting XRP stock in the short-term, while Bitcoin soars to record highs.

Ideanomics Still Looks Really Compelling as a Bet on EV Growth

By Chris Lau, InvestorPlace Contributor

Investors are speculating that Ideanomics will carve a niche in underserved EV markets like agriculture and motorbikes.

QuantumScape’s Long-term Battery Prospects Will Hold Charge

By Chris Lau, InvestorPlace Contributor

QuantumScape's deal with VW, which injects $100 million, plus the advanced technologies, is is one of many reasons to hold QS Stock.

7 Best Stocks on the Nasdaq

By Chris Lau, InvestorPlace Contributor

Investors need to hold the best companies that money can buy on the Nasdaq, amid a growing weakness in the technology stock index.

Load More